TY - JOUR
T1 - Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency
T2 - A quick review for a quick consultation
AU - Paolino, Giovanni
AU - Mercuri, Santo Raffaele
AU - Bearzi, Pietro
AU - Mattozzi, Carlo
N1 - Publisher Copyright:
© 2020 Wiley Periodicals LLC.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - The precision medicine era has helped to better manage patients with immunological and oncological diseases, improving the quality of life of this class of patients. Regarding the management of these patients and positivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), currently, limited data are available and information is evolving. In this quick review, we have analyzed the mechanisms of action and related infective risk of drugs used for the treatment of immune-mediated and oncologic skin conditions during the daily clinical practice. In general, immunosuppressant and antineoplastic agents for dermatologic treatments do not require suspension and do not require special measures, if not those commonly observed. In the case of a coronavirus disease (COVID-19) patient with complications (such as pneumonia, respiratory failure), treatment suspension should always be considered after taking into account the general condition of the patient, the risk-benefit ratio, and the pathophysiology of COVID-19 infection. The COVID-19 emergency pandemic does not imply undertreatment of existing skin conditions, which together with the SARS-CoV-2 infection may jeopardize the patient's life.
AB - The precision medicine era has helped to better manage patients with immunological and oncological diseases, improving the quality of life of this class of patients. Regarding the management of these patients and positivity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), currently, limited data are available and information is evolving. In this quick review, we have analyzed the mechanisms of action and related infective risk of drugs used for the treatment of immune-mediated and oncologic skin conditions during the daily clinical practice. In general, immunosuppressant and antineoplastic agents for dermatologic treatments do not require suspension and do not require special measures, if not those commonly observed. In the case of a coronavirus disease (COVID-19) patient with complications (such as pneumonia, respiratory failure), treatment suspension should always be considered after taking into account the general condition of the patient, the risk-benefit ratio, and the pathophysiology of COVID-19 infection. The COVID-19 emergency pandemic does not imply undertreatment of existing skin conditions, which together with the SARS-CoV-2 infection may jeopardize the patient's life.
KW - biologics
KW - COVID-19
KW - dermatologic treatments
KW - immunosuppressants
KW - SARS-CoV-2
KW - skin disease
KW - therapy systemic
UR - http://www.scopus.com/inward/record.url?scp=85084617611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084617611&partnerID=8YFLogxK
U2 - 10.1111/dth.13537
DO - 10.1111/dth.13537
M3 - Article
C2 - 32385891
AN - SCOPUS:85084617611
VL - 33
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 5
M1 - e13537
ER -